Benta Saudi will be positioned as a state-of-the-art specialized pharmaceutical facility in the Kingdom of Saudi Arabia, designed to become the region's premier hub for high-value biologics within the next 5–7 years.
The project aims to localize the production of oncology therapies, vaccines, monoclonal antibodies, biosimilars, sterile products and generics.
The strategy combines technology transfer, modular cGMP facility design and strategic local partnerships to drive capacity expansion, product diversification, and export growth across the GCC.
Aligned with Saudi Vision 2030 incentives and the National Biotechnology Strategy, Benta Saudi is intended to leverage sustainable practices to unlock synergies, optimize costs and generate compelling economic returns, in line with its strategic objectives.
